{
  "data": {
    "indicator": {
      "slug": "ctgov-rlt-phase-3-trials",
      "name": "Phase 3 radioligand therapy trials",
      "definition": "Count of interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy registered as Phase 3 or Phase 2/3, any start date.",
      "unit": "count",
      "scale": "1",
      "default_unit": "count",
      "default_scale": "1"
    },
    "scale": "1",
    "unit": "count",
    "region": {
      "code": "GLOBAL",
      "name": "Global",
      "type": "world"
    },
    "points": [
      {
        "period_start": "2026-09-27",
        "period_label": "as of 27 Sep 2026",
        "value": 51,
        "scale": "1",
        "unit": "count",
        "value_type": "actual",
        "statistic_id": "stat_XDEHC2J5C7XQKHC6VDH5K1AXHQ",
        "url": "https://statorigin.org/stat/stat_XDEHC2J5C7XQKHC6VDH5K1AXHQ",
        "source_org": "ClinicalTrials.gov",
        "source": {
          "org": "ClinicalTrials.gov (U.S. National Library of Medicine)",
          "org_short_name": "ClinicalTrials.gov",
          "document_title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27",
          "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=Lutetium%20OR%20177Lu%20OR%20Lu-177%20OR%20Actinium%20OR%20225Ac%20OR%20Ac-225%20OR%20%22Radium-223%22%20OR%20%22Radium%20223%22%20OR%20212Pb%20OR%20Pb-212%20OR%20%22radioligand%20therapy%22%20OR%20%22PSMA-617%22%20OR%20Terbium%20OR%20%22Copper-67%22%20OR%20%22lead-212%22%20OR%20Xofigo&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BPhase%5DPHASE3&countTotal=true&pageSize=1&fields=NCTId",
          "locator": "totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27.",
          "published_date": null
        }
      }
    ],
    "available_regions": [
      "GLOBAL"
    ]
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 1
  }
}